Sei Investments CO Puma Biotechnology, Inc. Transaction History

Sei Investments CO

$75 Billion
Q1 2025

A detailed history of Sei Investments CO transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Sei Investments CO holds 347,679 shares of PBYI stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

347,679

Previous 311,661 11.56%

Holding current value

$1.13 Million

Previous $922,000 11.61%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$2.76 - $3.88 $99,409 - $139,749	36,018 Added 11.56%	347,679 $1.03 Million
Q4 2024 Feb 11, 2025	BUY	$2.42 - $3.39 $56,093 - $78,576	23,179 Added 8.03%	311,661 $950,000
Q3 2024 Nov 12, 2024	SELL	$2.25 - $4.03 $2,373 - $4,251	-1,055 Reduced 0.36%	288,482 $735,000
Q2 2024 Aug 13, 2024	SELL	$2.92 - $5.83 $408 - $816	-140 Reduced 0.05%	289,537 $943,000
Q1 2024 May 07, 2024	SELL	$4.29 - $7.4 $9,399 - $16,213	-2,191 Reduced 0.75%	289,677 $1.54 Million
Q4 2023 Feb 14, 2024	BUY	$2.23 - $4.49 $13,850 - $27,887	6,211 Added 2.17%	291,868 $1.26 Million
Q3 2023 Nov 14, 2023	BUY	$2.63 - $4.09 $155 - $241	59 Added 0.02%	285,657 $751,000
Q2 2023 Aug 11, 2023	SELL	$2.6 - $3.58 $1,201 - $1,653	-462 Reduced 0.16%	285,598 $1.01 Million
Q1 2023 May 12, 2023	SELL	$2.21 - $4.82 $232 - $506	-105 Reduced 0.04%	286,060 $883,000
Q4 2022 Feb 10, 2023	BUY	$2.12 - $5.08 $1,937 - $4,643	914 Added 0.32%	286,165 $1.21 Million
Q3 2022 Nov 14, 2022	BUY	$2.27 - $3.84 $2,975 - $5,034	1,311 Added 0.46%	285,251 $676,000
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.3 $2,745 - $5,524	-1,674 Reduced 0.59%	283,940 $807,000
Q1 2022 May 13, 2022	BUY	$2.13 - $3.24 $3,282 - $4,992	1,541 Added 0.54%	285,614 $821,000
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $34,627 - $79,947	12,150 Added 4.47%	284,073 $863,000
Q3 2021 Nov 12, 2021	BUY	$6.63 - $9.39 $286,515 - $405,788	43,215 Added 18.9%	271,923 $1.9 Million
Q2 2021 Aug 06, 2021	BUY	$8.98 - $11.6 $683,171 - $882,493	76,077 Added 49.84%	228,708 $2.1 Million
Q1 2021 May 12, 2021	SELL	$9.38 - $13.63 $4,699 - $6,828	-501 Reduced 0.33%	152,631 $1.48 Million
Q4 2020 Feb 08, 2021	SELL	$7.78 - $12.13 $196,647 - $306,597	-25,276 Reduced 14.17%	153,132 $1.57 Million
Q3 2020 Nov 06, 2020	BUY	$9.5 - $11.14 $268,204 - $314,504	28,232 Added 18.8%	178,408 $1.8 Million
Q2 2020 Aug 17, 2020	SELL	$7.01 - $13.24 $7,227 - $13,650	-1,031 Reduced 0.68%	150,176 $1.57 Million
Q2 2020 Aug 11, 2020	BUY	$7.01 - $13.24 $13,059 - $24,666	1,863 Added 1.25%	151,207 $1.32 Million
Q1 2020 May 14, 2020	SELL	$6.28 - $14.57 $12,158 - $28,207	-1,936 Reduced 1.28%	149,344 $1.26 Million
Q4 2019 Feb 06, 2020	BUY	$6.5 - $10.73 $274,124 - $452,516	42,173 Added 38.65%	151,280 $1.32 Million
Q3 2019 Nov 12, 2019	BUY	$8.75 - $12.85 $840,778 - $1.23 Million	96,089 Added 738.12%	109,107 $1.17 Million
Q2 2019 Aug 14, 2019	SELL	$12.3 - $35.76 $323,145 - $939,486	-26,272 Reduced 66.87%	13,018 $164,000
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $498,916 - $1.02 Million	24,021 Added 157.32%	39,290 $1.52 Million
Q4 2018 Feb 13, 2019	BUY	$20.07 - $46.7 $291,275 - $677,757	14,513 Added 1919.71%	15,269 $327,000
Q3 2018 Nov 08, 2018	SELL	$41.2 - $59.85 $506,471 - $735,736	-12,293 Reduced 94.21%	756 $34,000
Q2 2018 Aug 03, 2018	SELL	$48.3 - $68.25 $212,423 - $300,163	-4,398 Reduced 25.21%	13,049 $771,000
Q1 2018 May 11, 2018	BUY	$59.7 - $99.25 $52,058 - $86,546	872 Added 5.26%	17,447 $1.19 Million
Q4 2017 Feb 08, 2018	BUY	$93.85 - $132.45 $1.35 Million - $1.91 Million	14,435 Added 674.53%	16,575 $1.64 Million
Q3 2017 Nov 06, 2017	BUY	$72.0 - $119.75 $154,080 - $256,265	2,140	2,140 $256,000

Others Institutions Holding PBYI

# of Institutions

116

Shares Held

31M

Call Options Held

32.7K

Put Options Held

200

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $148M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.

Account

Sei Investments CO Puma Biotechnology, Inc. Transaction History